Angiocrine Bioscience is a private, clinical-stage cell and gene therapy company harnessing the power of genetically modified human endothelial cells to regenerate tissues, restore function and rejuvenate patients with serious medical conditions.

Biotechnology

Angiocrine Bioscience

Paul Finnegan

Kathy K. Park

Gayle Bresnahan

Geoff Davis

Margie Breneman

John R. Jaskowiak

Lee Landeen

John Lomoro

John K. Fraser

Daniel J. Nolan

Michael Ginsberg

The Executive Administration team at Angiocrine Bioscience plays a pivotal role in strategic leadership and operational oversight. Comprised of top executives including the CEO, COO, CFO, and other key leaders, the team collaborates to drive the company's vision, streamline decision-making processes, and ensure effective governance to advance innovative therapies that improve patient outcomes.

Executive Administration

Leadership Team

Advisory Team

Executive Administration

About

Team members

Other teams at Angiocrine Bioscience

Leadership Team

Advisory Team